Company intelligence / Profile preview

KOMINOX

Siheung-si, Gyeonggi-do, South Koreakominox.com ↗

Ownership: Private
Development stage: Other

Overview

Kominox is an orally administered arsenic-based small molecule developed by Komipharm with demonstrated anticancer activity and cancer pain-relieving efficacy through gene expression regulation and signal pathway modulation. It has shown promising results in preclinical models and is being evaluated in multiple clinical trials across 14 metastatic cancer types including glioblastoma multiforme. The compound is also approved as a non-opioid cancer painkiller for animals by the Australian Therapeutic Goods Administration.

Therapeutic areas: NephrologyOncology
Modalities: Small molecule (specifically sodium metaarsenite/arsenic-based oral drug)
Industry: Biotech

Beyond the preview

Go deeper on KOMINOX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOMINOX.

Explore the full profile